PBYI Q2 2020 Earnings — Puma Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

PBYIPuma Biotechnology, Inc.

$299M

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$71M+30.9% YoY

Gross Profit

$61M86.7% margin

Operating Income

$7M10.1% margin

Net Income

$3M4.8% margin

EPS (Diluted)

$0.08

QoQ Revenue Growth

+37.8%

Cash Flow

Operating Cash Flow

$16M

Free Cash Flow

$16M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$264M

Total Liabilities

$240M

Stockholders' Equity

$23M

Cash & Equivalents

$91M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$71M	$54M	+30.9%
Gross Profit	$61M	$45M	+37.1%
Operating Income	$7M	-$26M	+127.7%
Net Income	$3M	-$37M	+109.1%

Revenue Segments

Product

$49M69%

License

$21M29%

Royalty

$1M2%